Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 8/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22483016 | 0.81 | HDAC6 (0.70) | HDAC6HDAC3HDAC8HDAC1HDAC11 | |
| SCHEMBL22482990 | 0.79 | HDAC6 (0.65) | HDAC6HDAC3HDAC8HDAC1HDAC11 | |
| SCHEMBL22482981 | 0.79 | HDAC6 (0.65) | HDAC6HDAC3HDAC8HDAC1HDAC11 | |
| SCHEMBL22483022 | 0.79 | HDAC6 (1.00) | HDAC6HDAC3HDAC8HDAC1HDAC11 | |
| SCHEMBL22482772 | 0.75 | HDAC6 (1.00) | HDAC6HDAC3HDAC8HDAC1HDAC11 | |
| SCHEMBL22483021 | 0.73 | HDAC6 (1.00) | HDAC6HDAC3HDAC8HDAC1HDAC11 | |
| SCHEMBL3611117 | 0.72 | HDAC6 (0.58) | HDAC6HDAC3HDAC8HDAC1HDAC11 | |
| SCHEMBL22039692 | 0.71 | HDAC6 (0.61) | HDAC6HDAC3HDAC8HDAC1HDAC11 | |
| SCHEMBL12472745 | 0.70 | HDAC6 (1.00) | HDAC6HDAC3HDAC8HDAC1HDAC11 | |
| SCHEMBL13261470 | 0.70 | HDAC6 (0.64) | HDAC6HDAC3HDAC8HDAC1HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169598-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | 2681603 ONTARIO INC. (CA) | 2022-06-02 | — | — | US | disclosed |
| WO-2020194272-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | 2681603 ONTARIO INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169598-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885HDAC3 4/4885HDAC8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.